# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.
Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and raises the price target from ...
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate o...
Raymond James analyst Sean McCutcheon reinstates Compass Therapeutics (NASDAQ:CMPX) with a Outperform and announces $9 price...
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate o...
D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.
CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inh...